Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
RESEARCH TOOLSreports
Outlook Therapeutics (OTLK) Stock Price & Analysis
1,120 Followers
OTLK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.01 - $36.98
Previous Close$7.08
Volume85.30K
Average Volume (3M)252.45K
Market Cap
$165.95M
Enterprise Value$163.46M
Total Cash (Recent Filing)$47.23M
Total Debt (Recent Filing)$44.74M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Aug 14, 2024EPS Estimate
-$1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.47
Shares Outstanding23,405,637
10 Day Avg. Volume229,222
30 Day Avg. Volume252,446
Standard Deviation0.37
R-Squared0.00839
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.44
Forecast
1Y Price Target
$35.00Price Target Upside394.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Outlook Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceOutlook has enough cash to operate into mid-2025, thanks to its recent capital raise.
Market PotentialONS-5010 would likely have significant pricing and reimbursement advantages, if approved.
Regulatory ProgressOutlook received a positive CHMP opinion for ONS-5010 (Lytenava/bevacizumab) in March which clears the path for EU approval this quarter.
Bears Say
Market DynamicsManagement noted there has been greater price compression in the branded anti-VEGF market in Europe (€400-€1,000 per dose in the EU versus $2,000 in the US market).
Product Quality ConcernsCompounded bevacizumab leaves much to be desired, as there are prevailing concerns surrounding manufacturing quality with implications ranging from diminished efficacy to potentially life-changing adverse events.
Regulatory IssuesThe FDA issued a Complete Response Letter for the BLA for ONS-5010, citing several CMC issues and open observations from pre-approval manufacturing inspections.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $4.01 and its highest was $36.98 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Currently, no data Available
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is Aug 14, 2024 which is in 40 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on May 15, 2024. The company reported -$1.55 earnings per share for the quarter, missing the consensus estimate of -$0.91 by -$0.64.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -$1.03.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 23,405,638 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$1.55 in its last earnings report, missing expectations of -$0.91. Following the earnings report the stock price went down -1.346%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Among the largest hedge funds holding Outlook Therapeutics’s share is Wexford Capital LP. It holds Outlook Therapeutics’s shares valued at N/A.
---
Outlook Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.00 (394.35% Upside)
$35.00 (394.35% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.26%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.
---
OTLK Earnings Call
Q2 2024
0:00 / 0:00
---
OTLK Stock 12 Month Forecast
Average Price Target
$35.00
▲(394.35% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Kala Pharmaceuticals
―
Ovid Therapeutics
―
Kodiak Sciences
―
Best Analysts Covering OTLK
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-8.80%
reiterated a buy rating last month
Copying Edward Woo's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -8.80% per trade.
---